Epigenetic-based therapies in the preclinical and clinical treatment of Huntington's disease

International Journal of Biochemistry and Cell Biology

Volumn 67, Issue , 2015, Pages 45-48

  Valor, Luis M ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Clinical trials; Epigenetics; HDAC inhibitors; Neurodegenerative; Transcription

Indexed keywords

3 HYDROXYBUTYRIC ACID; 4B; ANTHRACYCLINE; AR 42; BIOLOGICAL MARKER; BUTYRIC ACID; CHROMOMYCIN; CYCLOPEPTIDE; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2A; MACROH2A; MITHRAMYCIN; SELISISTAT; TUBACIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; CHROMATIN; HISTONE; NEUROPROTECTIVE AGENT;

ARTICLE; CHROMATIN; DRUG MECHANISM; ENZYME INHIBITION; EPIGENETICS; HUMAN; HUNTINGTON CHOREA; NEUROPATHOLOGY; NONHUMAN; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HUNTINGTON DISEASE; METABOLISM; PATHOLOGY; PRECLINICAL STUDY;

ANIMALS; ANTHRACYCLINES; CHROMATIN; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HUNTINGTON DISEASE; NEUROPROTECTIVE AGENTS; TRANSCRIPTION, GENETIC;

EID: 84940893279     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2015.04.009     Document Type: Review

References (43)

1. G. Bai, I. Cheung, H.P. Shulha, J.E. Coelho, P. Li, X. Dong, and et al. Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains Hum Mol Genet 24 5 2015 1441 1456
2. G. Bates, P. Harper, and L. Jones Huntington's disease 2004 Oxford University Press
3. A.V. Bieliauskas, and M.K. Pflum Isoform-selective histone deacetylase inhibitors Chem Soc Rev 37 2008 1402 1413
4. B. Biterge, and R. Schneider Histone variants: key players of chromatin Cell Tissue Res 356 2014 457 466
5. H.T. Bjornsson, J.S. Benjamin, L. Zhang, J. Weissman, E.E. Gerber, Y.C. Chen, and et al. Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome Sci Transl Med 6 2014 256ra135
6. J.M. Boutell, P. Thomas, J.W. Neal, V.J. Weston, J. Duce, P.S. Harper, and et al. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin Hum Mol Genet 8 1999 1647 1655
7. P. Chen, J. Zhao, and G. Li Histone variants in development and diseases J Genet Genom 40 2013 355 365
8. C. Choudhary, C. Kumar, F. Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, and et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 2009 834 840
9. M.E. Cudkowicz, P.L. Andres, S.A. Macdonald, R.S. Bedlack, R. Choudry, R.H. Brown Jr., and et al. Phase 2 study of sodium phenylbutyrate in ALS Amyotroph Lateral Scler 10 2009 99 106
10. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, and et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J Neurosci 23 2003 9418 9427
11. A. Fischer, F. Sananbenesi, A. Mungenast, and L.H. Tsai Targeting the correct HDAC(s) to treat cognitive disorders Trends Pharmacol Sci 31 2010 605 617
12. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group Cell 72 1993 971 983
13. P. Hogarth, L. Lovrecic, and D. Krainc Sodium phenylbutyrate in Huntington's disease: a dose-finding study Mov Disord 22 2007 1962 1964
14. Y. Hu, V. Chopra, R. Chopra, J.J. Locascio, Z. Liao, H. Ding, and et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse Proc Natl Acad Sci U S A 108 2011 17141 17146
15. H. Jia, C.D. Morris, R.M. Williams, J.F. Loring, and E.A. Thomas HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation Proc Natl Acad Sci U S A 112 2015 E56 E64
16. M. Jiang, J. Wang, J. Fu, L. Du, H. Jeong, T. West, and et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets Nat Med 18 2012 153 158
17. A. Kazantsev, E. Preisinger, A. Dranovsky, D. Goldgaber, and D. Housman Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells Proc Natl Acad Sci U S A 96 1999 11404 11409
18. T. Kouzarides Chromatin modifications and their function Cell 128 2007 693 705
19. Y. Li, T. Yokota, V. Gama, T. Yoshida, J.A. Gomez, K. Ishikawa, and et al. Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation Cell Death Differ 14 2007 2058 2067
20. J.P. Lopez-Atalaya, and A. Barco Can changes in histone acetylation contribute to memory formation? Trends Genet 30 2014 529 539
21. A. Mastrokolias, Y. Ariyurek, J.J. Goeman, E. van Duijn, R.A. Roos, R.C. van der Mast, and et al. Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood Eur J Hum Genet 2015 (Epub ahead of print)
22. E. Mercuri, E. Bertini, S. Messina, A. Solari, A. D'Amico, C. Angelozzi, and et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy Neurology 68 2007 51 55
23. F.C. Nucifora Jr., M. Sasaki, M.F. Peters, H. Huang, J.K. Cooper, M. Yamada, and et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity Science 291 2001 2423 2428
24. N. Osada, Y. Kosuge, K. Ishige, and Y. Ito Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases J Pharmacol Sci 122 2013 251 256
25. J. Pallos, L. Bodai, T. Lukacsovich, J.M. Purcell, J.S. Steffan, L.M. Thompson, and et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease Hum Mol Genet 17 2008 3767 3775
26. M.A. Reger, S.T. Henderson, C. Hale, B. Cholerton, L.D. Baker, G.S. Watson, and et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults Neurobiol Aging 25 2004 311 314
27. H. Ryu, J. Lee, S.W. Hagerty, B.Y. Soh, S.E. McAlpin, K.A. Cormier, and et al. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease Proc Natl Acad Sci U S A 103 2006 19176 19181
28. T. Shimazu, M.D. Hirschey, J. Newman, W. He, K. Shirakawa, N. Le Moan, and et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor Science 339 2013 211 214
29. C. Simoes-Pires, V. Zwick, A. Nurisso, E. Schenker, P.A. Carrupt, and M. Cuendet HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener 8 2013 7
30. S.F. Sleiman, D.E. Olson, M.W. Bourassa, S.S. Karuppagounder, Y.L. Zhang, J. Gale, and et al. Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition J Neurosci 34 2014 14328 14337
31. M.R. Smith, A. Syed, T. Lukacsovich, J. Purcell, B.A. Barbaro, S.A. Worthge, and et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease Hum Mol Genet 23 2014 2995 3007
32. E.C. Stack, S.J. Del Signore, R. Luthi-Carter, B.Y. Soh, D.R. Goldstein, S. Matson, and et al. Modulation of nucleosome dynamics in Huntington's disease Hum Mol Genet 16 2007 1164 1175
33. J.S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.Z. Zhu, H. Gohler, and et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription Proc Natl Acad Sci U S A 97 2000 6763 6768
34. G. Suske The Sp-family of transcription factors Gene 238 1999 291 300
35. S.D. Sussmuth, S. Haider, G.B. Landwehrmeyer, R. Farmer, C. Frost, G. Tripepi, and et al. An exploratory double blind, randomised clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease Br J Clin Pharmacol 79 2015 465 476
36. E.A. Thomas, G. Coppola, P.A. Desplats, B. Tang, E. Soragni, R. Burnett, and et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice Proc Natl Acad Sci U S A 105 2008 15564 15569
37. L.M. Valor Transcription, epigenetics and ameliorative strategies in Huntington's disease: a genome-wide perspective Mol Neurobiol 51 2015 406 423
38. L.M. Valor, and D. Guiretti What's wrong with epigenetics in Huntington's disease? Neuropharmacology 80 2014 103 114
39. M. Vashishtha, C.W. Ng, F. Yildirim, T.A. Gipson, I.H. Kratter, L. Bodai, and et al. Targeting H3K4 trimethylation in Huntington disease Proc Natl Acad Sci U S A 110 2013 E3027 E3036
40. I. Villar-Menendez, M. Blanch, S. Tyebji, T. Pereira-Veiga, J.L. Albasanz, M. Martin, and et al. Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease Neuromol Med 15 2013 295 309
41. H.H. Yeh, D. Young, J.G. Gelovani, A. Robinson, Y. Davidson, K. Herholz, and et al. Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease Brain Res 1504 2013 16 24
42. H. Yuan, and R. Marmorstein Structural basis for sirtuin activity and inhibition J Biol Chem 287 2012 42428 42435
43. D. Zadori, A. Geisz, E. Vamos, L. Vecsei, and P. Klivenyi Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease Pharmacol Biochem Behav 94 2009 148 153